A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of CAT-2054 in Combination With Atorvastatin in Patients With Hypercholesterolemia

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of CAT-2054 in Combination With Atorvastatin in Patients With Hypercholesterolemia

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Jun 2017

At a glance

  • Drugs Atorvastatin (Primary) ; CAT 2054 (Primary)
  • Indications Hypercholesterolaemia
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Catabasis Pharmaceuticals
  • Most Recent Events

    • 15 Jul 2016 Status changed from active, no longer recruiting to completed.
    • 07 Jun 2016 Results published in a Catabasis Pharmaceuticals media release.
    • 07 Jun 2016 Primary endpoint (Percent change in LDL-C from baseline in patients with hypercholesterolemia.) has not been met, according to a Catabasis Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top